- Home
- INO vs CCIF Comparison
INO vs CCIF Comparison
Compare INO & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- CCIF
- Stock Information
- Founded
- INO 1979
- CCIF 2011
- Country
- INO United States
- CCIF United States
- Employees
- INO 134
- CCIF N/A
- Industry
- INO Medical/Dental Instruments
- CCIF Finance/Investors Services
- Sector
- INO Health Care
- CCIF Finance
- Exchange
- INO Nasdaq
- CCIF Nasdaq
- Market Cap
- INO 128.1M
- CCIF 121.4M
- IPO Year
- INO 1998
- CCIF N/A
- Fundamental
- Price
- INO $2.37
- CCIF $5.52
- Analyst Decision
- INO Buy
- CCIF
- Analyst Count
- INO 5
- CCIF 0
- Target Price
- INO $8.80
- CCIF N/A
- AVG Volume (30 Days)
- INO 1.1M
- CCIF 76.9K
- Earning Date
- INO 11-13-2025
- CCIF 01-01-0001
- Dividend Yield
- INO N/A
- CCIF 25.90%
- EPS Growth
- INO N/A
- CCIF N/A
- EPS
- INO N/A
- CCIF N/A
- Revenue
- INO $182,337.00
- CCIF N/A
- Revenue This Year
- INO N/A
- CCIF N/A
- Revenue Next Year
- INO $15,960.33
- CCIF N/A
- P/E Ratio
- INO N/A
- CCIF N/A
- Revenue Growth
- INO N/A
- CCIF N/A
- 52 Week Low
- INO $1.30
- CCIF $7.43
- 52 Week High
- INO $5.83
- CCIF $10.16
- Technical
- Relative Strength Index (RSI)
- INO 54.07
- CCIF 37.18
- Support Level
- INO $2.38
- CCIF $5.67
- Resistance Level
- INO $2.58
- CCIF $5.95
- Average True Range (ATR)
- INO 0.14
- CCIF 0.12
- MACD
- INO -0.03
- CCIF -0.01
- Stochastic Oscillator
- INO 51.95
- CCIF 4.11
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.